Amgen

Open: 229.87 Close: 227.11 Change: -2.76

How to get informed about Amgen quickly using an AI.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, join, Amgens, California, state, block, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

California, other states join FTC bid to block Amgen deal to buy Horizon Therapeutics. Washington Attorney General Bob Ferguson said his state had joined the lawsuit because monopolies harm consumers.

Today's News

California, other states join FTC bid to block Amgen deal to buy Horizon Therapeutics. Washington Attorney General Bob Ferguson said his state had joined the lawsuit because monopolies harm consumers Amgen (AMGN) closed the most recent trading day at $227.11, moving -1.11% from the previous trading session. California, New York, Illinois, Minnesota, Washington and Wisconsin join FTC bid to block Amgen deal. Washington Attorney General Bob Ferguson said his state had joined the lawsuit because monopolies harm consumers Amgen continues to advance a robust development program for BLINCYTO, including studies aimed at treating patients with MRD-negative B-ALL. Janssen and Amgen settled their case regarding Amgens proposed biosimilar to Stelara in Delaware district court. Amgen has created a biosimilar called ABP 654, which has the same amino acid sequence as ustekinumab. The Supreme Court agreed on Friday, November 4, 2022, to review the standard for enablingment of genus claims after the Federal Circuits decision in Amgens, who Ru Feed Equipment messenger alumni remedMethods liberated probented Federal Trade Commission is seeking to block biopharmaceutical giant Amgen from acquisition that would Entrench Monopoly Drugs... FTC Sues to Block Biopharmatory Giant Amgen. Amgen-Horizon protest raises conglomerate concerns - law360. Amgen: FDA grants full approval for blincyto - quick facts. FTC Sues To Block Amgens $27.8 Bln Acquisition Of Horizon Therapeutics. California Attorney General: Amgens proposed acquisition of Horizon is dangerous for the future of medicine The company plans to continue what it calls a “robust development programme” for Blincyto. The FTC said last month it filing suit opposing the deal because it would give Amgen “monopoly positions” for medicines used to treat thyroid eye disease and chronic refractory gout. The FTC was specifically concerned that if Amgen were to engage in cross-market bundling products, it would allow the only FDA-approved medications. Amgen-Horizon acquisition challenge indicates that antitrust agencies are likely to closely scrutinize pharmaceutical mergers moving forward. FTCs suit against Amgen shows that the antitrust agencies now willing to challenge such transactions. Amgen is using cloud technology, DevSecOps framework to create a cloud operations platform that is used globally by Amgen development teams. The Director of Cloud Engineering will support commercial manufacturing at Amgen North Carolina.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

Are looking for the most relevant information about Amgen? Investor spend a lot of time searching for information to make investment decisions in Amgen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, join, Amgens, California, state, block, and the most common words in the summary are: amgen, news, event, new, company, report, state, . One of the sentences in the summary was: California, other states join FTC bid to block Amgen deal to buy Horizon Therapeutics. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #news #event #new #company #report #state.